Skip to main content

Table 2 Baseline characteristics of patients

From: Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis

RCTs

IMpassion130

KEYNOTE-355

IMpassion131

ALICE

This study

 

Cohorts

ICT

CT

ICT

CT

ICT

CT

ICT

CT

ICT

CT

Number of Participants

N = 902

N = 847

N = 651

N = 68

N = 2468

 

451 (50%)

451 (50%)

566 (67%)

281 (33%)

1448 (60%)

952 (40%)

40 (59%)

28 (41%)

1488 (60%)

980 (40%)

Age (median)

55 (46–64)

56 (47–65)

53 (44–63)

53 (43–63)

  

58.5 (31–77)

52.5 (28–74)

  

Race

  

White

308 (68%)

301 (67%)

384 (68%)

195 (69%)

246 (57%)

128 (58%)

  

1040 (70%)

732 (70%)

Asian

85 (19%)

76 (17%)

123 (22%)

52 (19%)

123 (29%)

66 (30%)

  

378 (25%)

235 (23%)

African-American

26 (6%)

33 (7%)

20 (4%)

17 (6%)

21 (5%)

10 (5%)

  

76 (5%)

75 (7%)

ECOG performance

  

0

256 (57%)

270 (60%)

332 (59%)

173 (62%)

262 (61%)

130 (59%)

27 (67.5%)

21 (75.0%)

877 (59%)

594 (61%)

1

193 (43%)

179 (40%)

232 (41%)

108 (38%)

169 (39%)

90 (41%)

13 (32.5%)

7 (25.0%)

552 (37%)

357 (36%)

PD-L1+

185 (41%)

184 (41%)

425 (75%)

211 (75%)

190 (44%)

101 (46%)

21 (52.5%)

10 (35.7%)

822 (55%)

506 (52%)

Metastatic disease

  

De novo metastasis

404 (89.8%)

408 (90.7%)

167 (30%)

84 (30%)

  

10 (25.0%)

8 (28.6%)

581 (39%)

493 (50%)

Lymph node

33 (7.3%)

23 (5.1%)

417 (74%)

206 (73%)

  

22 (55.0%)

13 (46.4%)

472 (32%)

242 (25%)

Bone

145 (32.2%)

141 (31.3%)

169 (30%)

85 (30%)

  

17 (42.5%)

16 (57.1%)

331 (22%)

242 (25%)

Lung

226 (50.1%)

242 (53.7%)

324 (57%)

162 (58%)

  

18 (45.0%)

10 (35.7%)

568 (38%)

414 (42%)

Liver

126 (28%)

118 (26%)

171 (30%)

78 (28%)

118 (27%)

61 (28%)

12 (30.0%)

13 (46.4%)

427 (29%)

270 (27%)

Number of metastatic sites

0–2

  

313 (55%)

166 (59%)

  

27 (67.5%)

15 (53.6%)

313 (21%)

166 (17%)

0–3

332 (74%)

341 (76%)

      

332 (22%)

341 (35%)

≥ 3

  

250 (44%)

115 (41%)

    

250 (17%)

115 (12%)

> 3

    

105 (24%)

48 (22%)

7 (17.5%)

3 (10.7%)

112 (7%)

51 (5%)

≥ 4

118 (26%)

108 (24%)

      

118 (8%)

108 (11%)

Previous chemo

284 (63%)

286 (63%)

357 (63%)

181 (64%)

313 (48%)

16 (40.0%)

12 (43.0%)

657 (44%)

479(49%)

Prior taxane

231 (51%)

230 (51%)

290 (51%)

156 (56%)

208 (48%)

107 (49%)

  

729 (50%)

493 (52%)

Prior anthracycline

243 (54%)

242 (54%)

318 (56%)

155 (55%)

212 (49%)

110 (50%)

28 (70.0%)

20 (71.4%)

801(54%)

527 (54%)

  1. Abbreviations: RCT = randomized controlled trial; N = number of participants; PD-L1 = programmed cell death ligand 1; ECOG = Eastern Cooperative Oncology Group; IT = immunotherapy.
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us